Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Gilead Sciences : China Food and Drug Administration Approves Gilead's Sovaldi® Sofosbuvir for Treatment of Chronic Hepatitis C Virus Infection

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:57pm CEST

By a News Reporter-Staff News Editor at Drug Week -- Gilead Sciences, Inc. (NASDAQ: GILD) announced that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Sovaldi was approved for the treatment of adults and adolescents (aged 12 to 18 years) infected with HCV genotype 1, 2, 3, 4, 5 or 6 as a component of a combination antiviral treatment regimen. Sovaldi is the first Gilead HCV medicine approved in China (see also Liver Diseases and Conditions - Chronic Hepatitis C Virus).

The approval of Sovaldi is supported by a Phase 3 study conducted in China, presented earlier this year at the Asian Pacific Association for the Study of the Liver (APASL) meeting. SVR12 (HCV RNA undetectable 12 weeks after completing therapy) rates for Chinese HCV patients with genotype 1, 2, 3 or 6 ranged from 92-100 percent. The study evaluated Sovaldi in combination with ribavirin (RBV) or pegylated interferon+ribavirin (PegIFN+RBV) across a range of difficult-to-cure patient populations, including treatment-experienced patients and those with compensated cirrhosis. In this study, the safety profiles of the regimens were consistent with the known side effects of pegylated interferon and/or ribavirin. The most common adverse events were hematological abnormalities and pyrexia.

Professor Lai Wei, the principal investigator of Sovaldi's Phase 3 study and former Chairman of the Chinese Society of Hepatology of the Chinese Medical Association said, "The approval of sofosbuvir in China provides more treatment options for Chinese HCV patients. The clinical trials in China and around the world provide evidence that the treatment is effective for multiple genotypes, which offers HCV patients in China a better chance at curing their disease."

HCV is the fourth-most commonly reported infectious disease in China, with approximately 10 million people infected. HCV genotypes 1, 2, 3 and 6 account for more than 96 percent of all cases. Less than one percent of HCV patients are currently treated, using interferon-based regimens that have lower efficacy, longer treatment duration and less favorable safety profiles than more recent regimens that contain direct-acting antiviral medicines.

"With the approval of Sovaldi, there is now the potential opportunity to transform treatment for HCV patients in China," said John F. Milligan, PhD, Gilead's President and Chief Executive Officer. "Medicines are one part of the solution but, as we have seen in other countries around the world, there are many other challenges that impact diagnosis, linkage to care and treatment. Gilead is committed to working with the government and other stakeholders with the goal to help reduce the significant burden of HCV disease in China."

Sovaldi received marketing approval from the U.S. Food and Drug Administration (FDA) in 2013 and the European Commission in 2014. It is also approved for use in 79 countries including Australia, India, Indonesia, the Philippines, New Zealand, Canada, Egypt, Switzerland and Turkey. Gilead Sciences in China Gilead has been present in China since 2007, starting with manufacturing and growing over time to include the establishment of commercial operations based in Shanghai in 2016.

Keywords for this news article include: Asia, Antivirals, Pharmaceutical Companies, China, Genetics, Cytokines, Ribavirin, Interferons, Purine Nucleosides, Respiratory Agents, Drugs and Therapies, Gilead Sciences Inc., Inhaled Antiinfectives, Respiratory Inhalant Products, Government Agencies Offices and Entities, Intercellular Signaling Peptides and Proteins.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES
06/22Celgenes CAR T Cell Therapy Could Be Long-Term Growth Driver
06/21GILEAD SCIENCES : Patent Issued for Method for Treating a Pulmonary Hypertension..
06/21GILEAD SCIENCES' : Chief Scientific Officer John McHutchison Appointed Officer o..
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
06/19BioCentury - Allogene names Schmidt CFO
06/19Payers, drugmakers face off over CAR T Medicare coverage
06/15Glaxo Pops But Analysts Say It`s Unlikely To Swipe Gilead Share In HIV
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
06/14GILEAD SCIENCES : Announces Leadership Changes in Corporate Development and Stra..
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/22ARBUTUS BIOPHARMA : The Next Big Breakout Biotech? 
06/21JOHNSON & JOHNSON : Strong Company, But Won't Fit In Most Portfolios 
06/211 High-Yield Blue Chip Set To Soar And 1 You Should Ignore 
06/203 THINGS IN BIOTECH, JUNE 19 : Geron Just Can't Win, Verastem Breaks Out 
Financials ($)
Sales 2018 20 794 M
EBIT 2018 10 734 M
Net income 2018 6 433 M
Debt 2018 13 028 M
Yield 2018 3,20%
P/E ratio 2018 14,36
P/E ratio 2019 13,08
EV / Sales 2018 5,07x
EV / Sales 2019 5,15x
Capitalization 92 410 M
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 85,8 $
Spread / Average Target 21%
EPS Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENMAB-3.97%9 557